AL-S PHARMA
AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.
AL-S PHARMA
Industry:
Health Care Medical
Founded:
2016-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Total Employee:
1+
Status:
Active
Total Funding:
0
Similar Organizations
Cellective BioTherapy
Cellective BioTherapy develops novel cellular and monoclonal antibody-based platforms to treat cancer, autoimmunity, and immunodeficiency.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Lumino
We are disrupting how healthcare is delivered, to help everyone enjoy better mental health.
Investors List
Neurimmune Holding
Neurimmune Holding investment in Seed Round - AL-S Pharma
TVM Capital Life Science
TVM Capital Life Science investment in Seed Round - AL-S Pharma